Loading…
Loading…
MYNDF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MYNDF and 80,000+ other tickers.
See exactly how MYNDF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MYNDF and 80,000+ other tickers.
MYND Life Sciences Inc. operates as a neuro-pharmaceutical company, applying life science principles to develop innovative treatments for depressive conditions. The firm conducts scientific research and clinical trials in Canada and the United States, concentrating on therapeutic compounds that possess neuro-anti-inflammatory properties. A significant part of its research involves the in-depth study of psilocin and psilocybin extracts, along with their various analogs. The company's principal office is situated in Kelowna, Canada.
Vancouver, British Columbia--(Newsfile Corp. - February 11, 2025) - MYND Life Sciences Inc. (CSE: MYND) (OTC Pink: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to the development and commercialization of drug therapies and diagnostics to improve the monitoring and treatment of depression, today announced that it has entered into shares for debt agreements (the "Agreements"), to satisfy an aggregate of $2,273,062.30 of the Company's outstanding debt (the "Indebtedness") related to loan, fees including all principal, accrued and unpaid interest, costs payments outstanding. An aggregate of 22,730,623 common shares in the capital of the Company (the "Shares") at a deemed price of $0.10 per Share are proposed to be issued to the creditors.
Vancouver, British Columbia--(Newsfile Corp. - January 17, 2025) - MYND Life Sciences (CSE: MYND) (OTC Pink: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to the development and commercialization of drug therapies and diagnostics to improve the monitoring and treatment of depression, today announced that the Board has approved the issuance of 4,000,001 common shares at $0.71/share in relation to the settlement of the $3.5 Million (CDN) of debenture announced on January 10, 2025. "We are pleased to announce that instructions to issue 4,000,001 shares for a total value of $2,840,000.71 in settlement of the debenture has been completed.
Vancouver, British Columbia--(Newsfile Corp. - January 10, 2025) - MYND Life Sciences (CSE: MYND) (OTC Pink: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to the development and commercialization of a biomarker tool for monitoring depression, today announced that the application to end its debenture has been successfully accepted by both the debenture holders and the regulatory commission. This announcement confirms the removal of $3.5 Million (CDN) of debt from its balance sheet.
Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a leader in mental health diagnostics and treatments, today announced two significant strategic decisions aimed at strengthening the company's financial position and governance. These moves demonstrate a strong commitment to the company's vision and strategic plan to commercialize a diagnostic biomarker test for depression which is being initially developed for the purpose of diagnosing and monitoring those with major depressive disorder (MDD).
Vancouver, British Columbia--(Newsfile Corp. - November 12, 2024) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to the development and commercialization of a biomarker tool for monitoring depression, today announced that subject to regulatory approval, it is proposing to issue 4 Million shares @ 0.71 per share to move $3.5 Million from its balance sheet, including the full restructure of an outstanding debenture on the business. "We are pleased to announce this important agreement to restructure our balance sheet to enhance both current and prospective shareholder value and to align with our strategic goals of optimizing our capital structure," MYND Life Sciences CEO, Colin Campbell commented.